Patents by Inventor Tsafi Pe'ery

Tsafi Pe'ery has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
    Patent number: 9849146
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: December 26, 2017
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • INHIBITION OF NONSENSE MEDIATED MRNA DECAY BY DRUGS THAT PREVENT HYPUSINATION OF EUKARYOTIC INITIATION FACTOR 5A
    Publication number: 20170319612
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: November 9, 2017
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Method of inhibiting nonsense-mediated mRNA decay
    Patent number: 9271998
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Grant
    Filed: November 18, 2013
    Date of Patent: March 1, 2016
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A
    Publication number: 20140206637
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked.
    Type: Application
    Filed: June 13, 2012
    Publication date: July 24, 2014
    Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY
    Publication number: 20140073685
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Application
    Filed: November 18, 2013
    Publication date: March 13, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut M. Hanauske-Abel
  • Method of inhibiting nonsense-mediated mRNA decay
    Patent number: 8603814
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: December 10, 2013
    Assignee: Rutgers the State University of New Jersey
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hogue, Hartmut Martin Hanauske-Abel
  • Abrogating HIV-1 Infection via Drug-Induced Reactivation of Apoptosis
    Publication number: 20120225093
    Abstract: The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection.
    Type: Application
    Filed: October 11, 2011
    Publication date: September 6, 2012
    Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY
    Inventors: Michael B. Mathews, Hartmut M. Hanauske-Abel, Tsafi Pe'ery, Mainul Hoque, Paul Palumbo, Deepti Saxena, Darlene D'Alliessi-Gandolfi, Myung-Hee Park
  • METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY
    Publication number: 20110039911
    Abstract: Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased.
    Type: Application
    Filed: July 20, 2010
    Publication date: February 17, 2011
    Inventors: Tsafi Pe'ery, Michael B. Mathews, Mainul Hoque, Hartmut Martin Hanauske-Abel
  • Variant Tat proteins and methods for use thereof
    Patent number: 7244814
    Abstract: Variants of the HIV-1 Tat protein exhibiting higher transcriptional activation and stronger P-TEFb binding than wild-type Tat are provided. In addition variants that can inhibit transcription activation by wild-type Tat are provided. Nucleic acid sequences encoding these variants, vectors and host cells for expression of these variants, and antibodies raised against these variants are also provided. In addition, methods for use of these variants and compositions containing these variants as research tools, as diagnostic tools and in the treatment of viral infections are provided.
    Type: Grant
    Filed: February 21, 2003
    Date of Patent: July 17, 2007
    Assignee: University of Medicine & Dentistry of New Jersey
    Inventors: Michael B. Mathews, Tsafi Pe'ery, Syed Reza
  • Variant tat proteins and methods for use thereof
    Publication number: 20050221288
    Abstract: Variants of the HIV-1 Tat protein exhibiting higher transcriptional activation and stronger P-TEFb binding than wild-type Tat are provided. In addition variants that can inhibit transcription activation by wild-type Tat are provided. Nucleic acid sequences encoding these variants, vectors and host cells for expression of these variants, and antibodies raised against these variants are also provided. In addition, methods for use of these variants and compositions containing these variants as research tools, as diagnostic tools and in the treatment of viral infections are provided.
    Type: Application
    Filed: February 21, 2003
    Publication date: October 6, 2005
    Inventors: Michael Mathews, Tsafi Pe'ery, Syed Reza